{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:25:05Z","timestamp":1787027105587,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Hyperemesis gravidarum is a serious pregnancy complication that affects approximately 1% of pregnancies worldwide.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To determine whether the use of ondansetron during pregnancy is associated with abnormal pregnancy outcomes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Search strategy:<\/jats:bold>\n                    PubMed, Cochrane Library, CINAHL, Embase, CNKI, CBM, WANFANG, and\n                    <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                    were searched for citations published in any language from inception to 15 December 2021.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Selection criteria:<\/jats:bold>\n                    Eligible studies included any observational study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Data collection and analysis:<\/jats:bold>\n                    Odds ratio (OR) and 95% confidence interval (CI) were used as indicators to examine the association between ondansetron and abnormal pregnancy outcomes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main results:<\/jats:bold>\n                    Twenty articles from 1,558 citations were included. Our preliminary analysis showed that compared with the unexposed group, the use of ondansetron during pregnancy may be associated with an increased incidence of cardiac defects (OR = 1.06, 95% CI: 1.01\u20131.10), neural tube defects (OR = 1.12, 95% CI: 1.05\u20131.18), and chest cleft (OR = 1.21, 95% CI: 1.07\u20131.37). Further sensitivity analysis showed no significant association between ondansetron and cardiac defects (OR = 1.15,95% CI: 0.94\u20131.40) or neural tube defects (OR = 0.87,95% CI: 0.46\u20131.66). When controversial studies were eliminated, the results for the chest defects disappeared. Simultaneously, we found that the use of ondansetron was associated with a reduced incidence of miscarriage (OR = 0.53, 95% CI: 0.31\u20130.89). Ondansetron was not associated with orofacial clefts (OR = 1.09,95% CI: 0.95\u20131.25), spinal limb defects (OR = 1.14,95% CI: 0.89\u20131.46), urinary tract deformities (OR = 1.06,95% CI: 0.97\u20131.15), any congenital malformations (OR = 1.03,95% CI: 0.98\u20131.09), stillbirth (OR = 0.97,95% CI: 0.83\u20131.15), preterm birth (OR = 1.22,95% CI: 0.80\u20131.85), neonatal asphyxia (OR = 1.05,95% CI: 0.72\u20131.54), or neonatal development (OR = 1.18,95% CI: 0.96\u20131.44) in our primary analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In our analysis, using ondansetron during pregnancy was not associated with abnormal pregnancy outcomes. Although our study did not find sufficient evidence of ondansetron and adverse pregnancy outcomes, future studies including the exposure period and dose of ondansetron, as well as controlling for disease status, may be useful to truly elucidate the potential risks and benefits of ondansetron.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.951072","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T10:50:06Z","timestamp":1662115806000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QiuYu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/bdra.22865","article-title":"Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects","volume":"94","author":"Anderka","year":"2012","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00228-005-0055-1","article-title":"Use of antiemetic drugs during pregnancy in Sweden","volume":"61","author":"Asker","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","unstructured":"Ondansetron 4 mg film-coated tablets - summary of product characteristics (SmPC) - (emc)2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jclinepi.2019.07.014","article-title":"New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy","volume":"116","author":"B\u00e9rard","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/AOG.0000000000001388","article-title":"Ondansetron use in pregnancy and birth defects: A systematic review","volume":"127","author":"Carstairs","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e068769","DOI":"10.1136\/bmj-2021-068769","article-title":"Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: Systematic review and meta-analysis","volume":"376","author":"Chaudhry","year":"2022","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"909860","DOI":"10.1155\/2013\/909860","article-title":"Off-label use of ondansetron in pregnancy in Western Australia","volume":"2013","author":"Colvin","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e11540","DOI":"10.7759\/cureus.11540","article-title":"A rise in aspartate transaminase and alanine transaminase associated with ondansetron administration in a pregnant female","volume":"12","author":"Couse","year":"2020","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bcpt.13541","article-title":"Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines agency (EMA) & pharmacovigilance risk assessment committee (PRAC)","volume":"128","author":"Damkier","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.reprotox.2014.10.017","article-title":"Use of ondansetron during pregnancy and congenital malformations in the infant","volume":"50","author":"Danielsson","year":"2014","journal-title":"Reprod. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e215329","DOI":"10.1001\/jamanetworkopen.2021.5329","article-title":"Comparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort","volume":"4","author":"Dormuth","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1471-0528.2004.00236.x","article-title":"The safety of ondansetron for nausea and vomiting of pregnancy: A prospective comparative study","volume":"111","author":"Einarson","year":"2004","journal-title":"BJOG"},{"key":"B14","first-page":"e171","article-title":"Quantifying the global rates of nausea and vomiting of pregnancy: A meta analysis","volume":"20","author":"Einarson","year":"2013","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/AOG.0000000000002604","article-title":"ACOG practice bulletin 189: Nausea and vomiting of pregnancy","volume":"131","author":"Erick","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.reprotox.2016.04.027","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States","volume":"62","author":"Fejzo","year":"2016","journal-title":"Reprod. Toxicol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41572-019-0110-3","article-title":"Nausea and vomiting of pregnancy and hyperemesis gravidarum","volume":"5","author":"Fejzo","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B18","first-page":"e1","article-title":"Ondansetron use during pregnancy: A case series","volume":"19","author":"Ferreira","year":"2012","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/ppe.12416","article-title":"Adverse maternal and birth outcomes in women admitted to hospital for hyperemesis gravidarum: A population- based cohort study","volume":"32","author":"Fiaschi","year":"2018","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/1471-0528.15662","article-title":"Clinical management of nausea and vomiting in pregnancy and hyperemesis gravidarum across primary and secondary care: A population-based study","volume":"126","author":"Fiaschi","year":"2019","journal-title":"BJOG"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.smrv.2019.101215","article-title":"Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies","volume":"48","author":"Ge","year":"2019","journal-title":"Sleep. Med. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/fcp.12681","article-title":"What changes in prescription patterns of antiemetic medications in pregnant women in France?","volume":"35","author":"Hurault-Delarue","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jama.2019.18587","article-title":"Intravenous ondansetron in pregnancy and risk of congenital malformations","volume":"323","author":"Huybrechts","year":"2020","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.reprotox.2019.03.001","article-title":"Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis","volume":"86","author":"Kaplan","year":"2019","journal-title":"Reprod. Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ajog.2014.08.017","article-title":"Treating morning sickness in the United States\u2014changes in prescribing are needed","volume":"211","author":"Koren","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jogc.2017.10.024","article-title":"Ondansetron in pregnancy and the risk of congenital malformations: A systematic review","volume":"40","author":"Lavecchia","year":"2018","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"B28","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/ije\/dyz255","article-title":"Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect","volume":"49","author":"Lemon","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1002\/phar.1796","article-title":"Ondansetron exposure changes in a pregnant woman","volume":"36","author":"Lemon","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ajo.13084","article-title":"SOMANZ position paper on the management of nausea and vomiting in pregnancy and hyperemesis gravidarum","volume":"60","author":"Lowe","year":"2020","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B32","first-page":"81","article-title":"The safety of ondansetron and chlorpromazine for hyperemesis gravidarum in first trimester pregnancy","volume":"20","author":"\u00d6zdemirci","year":"2014","journal-title":"Gynecol. Obstet. Reprod. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/AOG.0000000000002679","article-title":"Ondansetron for treatment of nausea and vomiting of pregnancy and the risk of specific birth defects","volume":"132","author":"Parker","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1056\/NEJMoa1211035","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes","volume":"368","author":"Pasternak","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/bdr2.1705","article-title":"Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis","volume":"112","author":"Picot","year":"2020","journal-title":"Birth Defects Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/ajo.12045","article-title":"A survey of prescribing for the management of nausea and vomiting in pregnancy in Australasia","volume":"53","author":"Raymond","year":"2013","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.reprotox.2020.11.005","article-title":"Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study","volume":"99","author":"Sakran","year":"2021","journal-title":"Reprod. Toxicol."},{"key":"B38","volume-title":"The management of nausea and vomiting of pregnancy and hyperemesis gravidarum (Green-top guideline No. 69)","author":"Shehmar","year":"2016"},{"key":"B39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/pds.5151","article-title":"Ondansetron use in early pregnancy and the risk of late pregnancy outcomes","volume":"30","author":"Suarez","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/pds.4185","article-title":"Antiemetic use among pregnant women in the United States: The escalating use of ondansetron","volume":"26","author":"Taylor","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/CLEP.S287892","article-title":"Antiemetic prescription fills in pregnancy: A drug utilization study among 762, 437 pregnancies in Norway","volume":"13","author":"van Gelder","year":"2021","journal-title":"Clin. Epidemiol."},{"key":"B43","volume-title":"The newcastle-ottawa scale (NOS) for assessing the quality of non randomised studies in meta-analyses","author":"Wells","year":"2001"},{"key":"B44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/aje\/kwu096","article-title":"Medication use in pregnancy in relation to the risk of isolated clubfoot in offspring","volume":"180","author":"Werler","year":"2014","journal-title":"Am. J. Epidemiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.reprotox.2018.10.010","article-title":"First trimester ondansetron exposure and risk of structural birth defects","volume":"83","author":"Zambelli-Weiner","year":"2019","journal-title":"Reprod. Toxicol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.951072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T10:50:15Z","timestamp":1662115815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.951072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":45,"alternative-id":["10.3389\/fphar.2022.951072"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.951072","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.170670877.75641463\/v1","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"article-number":"951072"}}